Global Regulatory Roundup: Key Updates for June 1, 2026

Key Takeaways

• FDA published draft guidance on accelerated approval and when a confirmatory trial is underway under CAA 2023 authorities.
• Project Confirm at FDA’s Oncology Center of Excellence frames accelerated approval as contingent on timely verification of clinical benefit.
• Sponsors should plan confirmatory enrollment early; FDA has signaled trials should be well underway near accelerated approval.
• Unverified non-U.S. agency “week of June 1” claims without primary agency pages were removed from this rewrite.

What Did FDA Clarify on Accelerated Approval?

FDA’s draft guidance, Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway, interprets the CAA 2023 amendment to section 506(c) of the FD&C Act. That amendment allows FDA to require confirmatory studies to be underway before approval or within a specified period after approval. The draft, issued by the Oncology Center of Excellence (docket FDA-2024-D-3334), sets out how the agency intends to judge whether a trial is underway.

For BD teams, the practical message is timing: confirmatory protocols and enrollment plans need to be credible before an accelerated-approval filing, not after commercial launch.

How Does Project Confirm Change Oncology Diligence?

FDA Project Confirm explains that accelerated approval still requires confirmatory trials to verify clinical benefit, and that FDA may require those trials to be underway at approval. Postmarketing requirements include projected completion and final-report dates. Confirmatory trials already enrolling at approval are more likely to finish on time.

• Accelerated approval remains available for serious conditions with meaningful advantage over available therapy.
• Confirmatory studies are a condition of continued approval, not an optional follow-on.
• Enrollment risk after approval is a known failure mode FDA is trying to reduce.

What Should Sponsors Do Before Filing?

FDA’s related oncology communications, including materials hosted on fda.gov media downloads on confirmatory-trial timing, emphasize early discussion of confirmatory design and feasibility. Sponsors should document enrollment assumptions, competing-trial landscapes, and how accelerated approval itself might slow later randomization.

Investors diligence should ask whether a late-stage oncology asset’s confirmatory plan is already recruiting, partially enrolled, or still a paper protocol.

What About Non-Oncology Categories Such as Dermatologicals?

This roundup’s primary-source spine is oncology accelerated-approval policy. Broader therapeutic areas, including dermatologicals and neurology, may feel indirect effects as FDA modernizes postmarketing expectations, but those category-specific June 1, 2026 agency actions are not asserted here without primary agency notices.

What Remains Unproven This Week?

Secondary roundup wires sometimes list TGA shortage dashboards, ANVISA/COFEPRIS calendars, or named Phase III readouts as if they were FDA actions. Without allowlisted regulator pages for those items in this rewrite, they are omitted. The sourced U.S. signal is confirmatory-trial readiness for accelerated approval.

Related NovaPharma coverage

• Sanofi pipeline: Dupixent, Lantus and 2026 catalysts
• Eli Lilly pipeline and deals outlook
• Dermatologicals disease hub

Frequently Asked Questions

Primary Sources

1. FDA — Accelerated Approval confirmatory trial “underway” guidance
2. FDA — Project Confirm (Oncology Center of Excellence)
3. FDA media — confirmatory trial timing discussion materials